Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 35, 2018 - Issue 7-8
Submit an article Journal homepage
268
Views
3
CrossRef citations to date
0
Altmetric
Reports

Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung

Ben W.R. BalzerSydney Children’s Hospital, Randwick, New South Wales, Australia; ;School of Women’s and Children’s Health, University of New South Wales, Randwick, New South Wales, Australia; ORCID Iconhttp://orcid.org/0000-0001-7116-2339View further author information
ORCID Icon,
Christine LooDepartment of Anatomical Pathology, NSW Health Pathology, Prince of Wales Hospital, Randwick, New South Wales, Australia; View further author information
,
Eva A. WegnerDepartment of Nuclear Medicine and PET, Prince of Wales Hospital, Randwick, New South Wales, Australia; ;Prince of Wales Clinical School, University of New South Wales, Randwick, New South Wales, Australia; View further author information
,
Christa E. NathDepartment of Biochemistry, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia; ;Faculty of Pharmacy, University of Sydney, Camperdown, New South Wales, Australia; ORCID Iconhttp://orcid.org/0000-0002-1013-3646View further author information
ORCID Icon,
Samiuela LeeDepartment of Biochemistry, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia; View further author information
,
Chantelle SmithPharmacy Department, Sydney Children’s Hospital, Randwick, New South Wales, Australia; View further author information
,
Craig R. LewisPrince of Wales Clinical School, University of New South Wales, Randwick, New South Wales, Australia; ;Department of Medical Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia; View further author information
,
Toby N. TrahairSydney Children’s Hospital, Randwick, New South Wales, Australia; ;School of Women’s and Children’s Health, University of New South Wales, Randwick, New South Wales, Australia; ;Sydney Children’s Hospital, Kids Cancer Centre, Randwick, New South Wales, Australia; ORCID Iconhttp://orcid.org/0000-0002-3295-228XView further author information
ORCID Icon &
Antoinette C. AnazodoSydney Children’s Hospital, Randwick, New South Wales, Australia; ;School of Women’s and Children’s Health, University of New South Wales, Randwick, New South Wales, Australia; ;Sydney Children’s Hospital, Kids Cancer Centre, Randwick, New South Wales, Australia; ;Prince of Wales Hospital, Nelune Comprehensive Cancer Centre, Randwick, New South Wales, AustraliaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5495-6062View further author information
ORCID Icon show all
Pages 415-421 | Received 19 Aug 2018, Accepted 23 Oct 2018, Published online: 09 Dec 2018

References

  • Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
  • Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017;389(10072):917–929.
  • Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017;390(10089):29–39.
  • Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838.
  • Mosse YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children's oncology group study. JCO 2017;35(28):3215–3221.
  • Kim SJ, Kim DW, Kim TM, Lee SH, Heo DS, Bang YJ. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer. JCO 2012;30(16):e147–e150.
  • Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472–480.
  • Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest 2017;151(1):193–203.
  • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Canc. 2009;45(2):228–247.
  • Morcos PN, Nueesch E, Jaminion F, et al. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2018;82(1):129–138.
  • Thai AA, Solomon BJ. Treatment of ALK-positive non-small cell lung cancer: recent advances. Curr Opin Oncol. 2018;30(2):84–91.
  • Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–381.
  • Zhu V, Ou SH. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf. 2017;16(4):509–514.
  • Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409–1416.
  • Sato-Nakai M, Kawashima K, Nakagawa T, et al. Metabolites of alectinib in human: their identification and pharmacological activity. Heliyon 2017;3(7):e00354.
  • International Council on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Addendum to ICH E11: Clinical Investigation of Medicinal Products in the Pediatric Population E11 (R1); 2017.
  • Heath JA, Campbell MA, Thomas A, Solomon B. Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma. Pediatr Blood Cancer. 2018;65(7):e27055
  • Carpenter EL, Mosse YP. Targeting ALK in neuroblastoma-preclinical and clinical advancements. Nat Rev Clin Oncol. 2012;9(7):391–399.
  • Usmani S, Marafi F, Rasheed R, Al Maraghy M, Al Kandari F. Targeted therapy with anaplastic lymphoma kinase inhibitor (alectinib) in adolescent metastatic non-small cell lung carcinoma: 18F-NaF PET/CT in response evaluation. Clin Nucl Med. 2018;43(10):752–754.
  • Balzer BWR, Loo C, Lewis CR, Trahair TN, Anazodo AC. Adenocarcinoma of the lung in childhood and adolescence: a systematic review. J Thoracic Oncol. 2018;13(12):1832–1841. doi:10.1016/j.jtho.2018.1008.2020.
  • Fan J, Xia Z, Zhang X, et al. The efficacy and safety of alectinib in the treatment of ALK + NSCLC: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:1105–1115.
  • Gainor JF, Chi AS, Logan J, et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol. 2016;11(2):256–260.
  • Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374(1):54–61.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.